Assembly Biosciences ASMB

$19.84 -0.44 (-2.17%)

Valuation

Market cap
403,962,000
Revenue TTM
$72,300,000
Net income TTM
$-6,120,000
PE ratio
19.88
Forward PE
8.89
Profit margin
-8.46%
Debt to equity
0.00

Trading

Volume
206,000
Avg volume
322,546
Day's range
$19.30 – $20.34
Shares out
20,361,000
Stochastic %K
16%
Beta
1.15
Analysts
Strong Sell
Price target
$49.67

Price

Company profile

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for...

Show more

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
833 509 4583
Website
https://www.assemblybio.com
Address
Two Tower Place, 7th Floor, South San Francisco, United States

Latest news

Stocktwits

mktrdr59 Oct 25, 9:39 PM
$ASMB reaching measured move price projection at Fib .618 retracement, with bullish divergences on the technical indicators.
0 replies
IchimokuSwingTrading Oct 23, 3:21 PM
$ASMB These are very very low prices, but the bottom is not in yet. Can't believe it's the teens. I'll buy more once the bottom is in and I see a reversal of some sort.
1 replies
DomLuminous Oct 23, 2:24 PM
$GILD Keeps pressing higher keep an eye on $ASMB I think that has a mega rip coming. Gilead is keen on their research.
1 replies
ShinnosukeNohara Oct 21, 10:23 PM
$ASMB
0 replies
Stronx Oct 21, 7:48 PM
$ASMB Buy some more!!
0 replies
ShinnosukeNohara Oct 21, 9:45 AM
$ASMB https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-gsks-hepatitis-b-drug-offering-patients-chance-stop-long-term-2026-10-20/
0 replies
ShinnosukeNohara Oct 16, 3:44 PM
$ASMB
0 replies
SearchFor911 Oct 14, 11:10 AM
$ASMB if you haven't figured it out yet, you will very soon. 🚨
3 replies